Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vor Biopharma Inc VOR

Healthcare Biotechnology
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VOR)

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2025

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

GlobeNewswire November 10, 2025

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

GlobeNewswire November 10, 2025

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

GlobeNewswire November 8, 2025

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2025

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

GlobeNewswire November 3, 2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 31, 2025

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

GlobeNewswire October 29, 2025

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

GlobeNewswire October 22, 2025
View More News ››

Opinion & Analysis (NDAQ:VOR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VOR)

Using technical analysis for this stock.

It is starting a big uptrend and it's looking really good here for shareholders today
coolfooldumbguy - August 13, 2025

VOR....$1.19 now ; )

Bot some on that last dip to $1.10 LFG !
Iseneschal - June 26, 2025

VOR.....Trending higher now at $1.14

The H.oD this a.m was $1.22 It'll probaly bust thru that JMHO
Iseneschal - June 26, 2025

VOR....$175 mil P.O

THey mean business ; ) Big financing normally pay off big No position unfortunately ; )
Iseneschal - June 26, 2025

Vor Bio (NASDAQ:VOR) &#8211; A Promising Cell and Genome Eng

http://beyondspx.com/2024/08/01/vor-bio-nasdaqvor-a-promising-cell-and-genome-engineering-firm-poised-for-transformation/
MikeTester - August 2, 2024
View more Bullboard ››

Pelangio Exploration Inc.

Pelangio Exploration Inc.

Pelangio Exploration Inc., a mineral exploration company, engages in the acquisition, exploration, and development of mineral ...
View More »